A Study on the Effectiveness of Mono and Dual Antiplatelet Therapy in Secondary Prevention of Vascular Events
DOI:
https://doi.org/10.53555/jaz.v45i2.4080Keywords:
Dual Antiplatelet Therapy, Secondary Prevention, Vascular EventsAbstract
The aim of the study was to determine whether addition of aspirin to clopidogrel could have a greater benefit than clopidogrel alone in the prevention of secondary vascular events in patients after TIA or ischemic stroke. Out of the total patients, 34.2 % of patients had recurrence of vascular events. 36.3 % patients reached the primary endpoint in the group receiving dual therapy compared to 20% in the monotherapy group. 31% in dual therapy group had Ischemic stroke as qualifying event compared to 5 % in monotherapy. Our study focused on the prevalence of risk factors in patients with recurrence of vascular events. Risk factors found were previous ischemic stroke in 12 % of dual therapy group and 1% in mono group. Hypertension was found in 30 % of dual group and 3 % of mono group. Diabetes was risk factor in 16% of dual therapy patients and 4% in mono group Hypercholesterolemia was found in 19% of dual group and 4 % of mono group11% of dual therapy patients and 2 % of mono therapy patients were smokers. The primary events were found to have a significant association with gender, risk factors and therapy. No bleeding complications were observed in the study population.
Downloads
References
Centers for Disease Control and Prevention. Stroke facts. https://www.cdc.gov/stroke/facts.hmt.Accessed November 20, 2018.
Amarenco P, Lavallée PC, Labreuche J, et al. One-year risk of stroke after transient ischemic attack or minor stroke. N Engl J Med 2016;374(16):1533–1542. 10.1056/NEJMoa1412981 [PubMed] [CrossRef] [Google Scholar]
Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA. 2000;284(22):2901–2906. [PubMed] [Google Scholar]
Hill MD, Yiannakoulias N, Jeerakathil T, Tu JV, Svenson LW, Schopflocher DP. The high risk of stroke immediately after transient ischemic attack: A population-based study. Neurology. 2004;62(11):2015–2020. 10.1212/01.WNL.0000129482.70315.2F. [PubMed] [CrossRef] [Google Scholar]
Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49(3). 10.1161/STR.0000000000000158 [PubMed] [CrossRef] [Google Scholar]
CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet. 1997;349(9066):1641–1649. doi:S0140673697040105[pii] [PubMed] [Google Scholar]
The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet (London, England). 1997;349(9065):1569–1581. Accessed May 3, 2019. [PubMed] [Google Scholar]
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet (London, England). 1996;348(9038):1329–1339. Accessed May 3, 2019. [PubMed] [Google Scholar]
ESPRIT Study Group, Halkes PHA, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367(9523):1665–1673. 10.1016/S0140-6736(06)68734-5 [PubMed] [CrossRef] [Google Scholar]
Sacco RL, Diener H-C, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359(12):1238–1251. 10.1056/nejmoa0805002 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack for the CHANCE Investigators*. N Engl J Med. 2013;369(1):11–19. 10.1056/NEJMoa1215340 [PubMed] [CrossRef] [Google Scholar]
Wang X, Zhao X, Johnston SC, et al. Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke. Neurology. 2015;85(7):573–579. 10.1212/WNL.0000000000001844 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018;379(3):215–225. 10.1056/NEJMoa1800410 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Diener H-C, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331–337. 10.1016/S0140-6736(04)16721-4 [PubMed] [CrossRef] [Google Scholar]
SPS3 Investigators, Benavente OR, Hart RG, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012;367(9):817–825. 10.1056/NEJMoa1204133 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Wang C, Yi X, Zhang B, Liao D, Lin J, Chi L. Clopidogrel plus aspirin prevents early neurologic deterioration and improves 6-month outcome in patients with acute large artery atherosclerosis stroke. Clin Appl Thromb. 2015;21(5):453–461. 10.1177/10760 [PubMed] [CrossRef] [Google Scholar]
Hong K-S, Lee S-H, Kim EG, et al. Recurrent ischemic lesions after acute atherothrombotic stroke. Stroke. 2016;47(9):2323–2330. 10.1161/strokeaha.115.012293 [PubMed] [CrossRef] [Google Scholar]
N.Manichandana, V. Srilatha, B.Vijatha, R.Tulsi, Dr.Amatul Ali Sameera, Neurological Disorders And Diseases: Prevalence And Incidence In Tertiary Care Hospital.,Indo Am. J. P. Sci, 2022; 09(6). [Google Scholar]
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Suroju Nikhil Chary, Jupaka Rohith, Pothappa Rishik Chary, Sehrish Tazeen, Amatul Ali Sameera
This work is licensed under a Creative Commons Attribution 4.0 International License.
